Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Esther Lange

Nurse Practitioner, Gerontology Birmingham, AL Nurse Practitioner

NPI 1932760105 CMS profile 10582497

504 Brookwood Blvd, Birmingham, AL 35209

Open in the dashboard

General payments

$9,512

313 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Esther Lange of Birmingham, AL is reported in the CMS Open Payments database as having received $9,512 across 313 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,301 95
2024 General $1,318 52
2023 General $2,998 57
2022 General $1,003 59
2021 General $890 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Esther Lange
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Esther Lange were reported at $3,301. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Esther Lange Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $890 $133 $44–$396 $132
2022 $1,003 $142 $48–$452 $149
2023 $2,998 $158 $53–$482 $160
2024 $1,318 $171 $55–$533 $164
2025 $3,301 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $2,136 22 payments
  2. Novartis Pharmaceuticals Corporation $1,372 22 payments
  3. OptiNose US, Inc. $824 51 payments
  4. CSL Behring $732 21 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $708 33 payments
  6. Genentech USA, Inc. $591 21 payments
  7. Amgen Inc. $454 28 payments
  8. GlaxoSmithKline, LLC. $389 17 payments
  9. Grifols USA, LLC $376 18 payments
  10. Regeneron Healthcare Solutions, Inc. $354 20 payments
  11. Other $1,575 60 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,364 306 payments
  2. Travel and Lodging $2,148 7 payments
Products named General payments · program years 2021–2025
  1. Rhapsido $1,207 13 payments
  2. Xhance $824 51 payments
  3. Xolair $591 21 payments
  4. TEZSPIRE $414 25 payments
  5. NUCALA $389 17 payments
  6. Xembify $376 18 payments
  7. DUPIXENT $354 20 payments
  8. CUVITRU $352 18 payments
  9. TAKHZYRO $334 14 payments
  10. PANZYGA $309 16 payments
  11. Other $2,877 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record